Skip to content

    Lupin Limited

    LUPIN
    Healthcare·15 May 2025
    Management Summary

    Lupin reported a stellar FY25 with strong revenue and EBITDA growth, driven by robust performance in the US and India markets. Margin expansion was significant, and the company achieved a zero-debt status. While adjacency businesses are still in investment phase and loss-making, the core business shows strong momentum with a focus on complex generics and chronic therapy areas.

    Highlights

    5

    • FY25 revenue of USD 2.7 billion and EBITDA of USD 625 million, demonstrating strong growth momentum.

    • EBITDA margins expanded to 23.2% in Q4 FY25, with an adjusted core margin of 26% after accounting for adjacencies and PLI.

    • US business achieved 17% growth in FY25, driven by complex generics which now constitute 30% of US revenues.

    • India business grew 14% in FY25, with chronic share improving to 64% and a target of 69-70% by FY30.

    • Company is now zero-debt and cash surplus, with FY25 free cash flow of INR 1,330 crores.

    Concerns

    3

    • India's in-licensed product portfolio experienced de-growth of 12% in FY25 due to loss of exclusivity, impacting overall India growth.

    • Adjacency businesses (diagnostics, digital health, OTC, CDMO) are currently loss-making, impacting overall EBITDA margin by 3.5-3.7 percentage points.

    • Two manufacturing sites (Mandideep and Tarapur) are still awaiting FDA approval, though management expresses confidence in their readiness.

    What Changed2

    vs Q1 FY26

    Guidance items16 → 13 (-3)Risks discussed7 → 3 (-4)

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue$2.7B
    2. 02EBITDA625 Mn
    3. 03EBITDA Margin23.2%
    4. 04Gross Margin69.2%
    5. 05ROCE20%

    Segment breakdown

    US
    925 Mn Revenue17% Growth30% Complex Generics Share
    India
    14.0% Growth64% Chronic Share-12% In-license Portfolio De-growth
    EMEA
    22% Growth55% Complex Generics Share
    LATAM
    10% Growth
    APAC
    5% Growth
    ROW/GIB
    11% Growth
    API
    3% Growth
    Lupin Diagnostics
    44% Revenue Growth
    Lupin Life (OTC)
    ₹150 Cr Revenue
    List

    Capital allocation

    7
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Net ₹0 crores · 0.0x EBITDA

    M&A

    Lilly's insulin brand

    acquisition · closed

    M&A

    Medisol

    acquisition · closed

    M&A

    Southern Cross

    acquisition · closed

    Guidance & targets

    13
    CategoryTargetPriority
    India Business Growth
    India market growth multiple
    1.2-1.3 times the market
    		High
    India Sales Force Expansion
    Number of representatives added
    400-500 representatives
    		High
    India New Product Launches
    Number of NPLs
    80 products
    		High
    India Chronic Share
    Percentage of sales from chronic products
    69-70%
    		High
    Lupin Life (OTC) Revenue
    Revenue growth
    more than double
    		Medium
    Lupin Diagnostics Profitability
    EBITDA status
    EBITDA positive
    		High
    US Complex Generics Share
    Percentage of US revenues
    49%
    		High
    US Complex Generics Share
    Percentage of US revenues
    55%
    		High
    Europe Complex Generics Share
    Percentage of Europe business
    two-thirds
    		High
    R&D Spend
    R&D spend as % of sales
    upward of 8.5%
    		High
    EBITDA Margin
    EBITDA margin trend
    continuously go up
    		Medium
    ROCE
    ROCE percentage
    27-28%
    		Medium
    Debt
    Debt to EBITDA ratio
    around 2:1
    		Medium

    What to watch in Q1 FY26

    5

    FDA approval status of Mandideep and Tarapur sites

    near future
    CurrentAwaiting FDA approval
    TargetFDA approval received

    Why it matters

    Resolution of these sites is crucial for full operational flexibility and potential new product approvals.

    I am confident if the FDA was to visit the 2 pending sites, Mandideep as well as Tarapur, our sites are ready to receive them. But we don't have any pending products from the sites, so they don't have any hurry to come in and inspect these sites. But I am confident in the near future we will get those sites cleared as well.

    Risks & concerns

    3
    RiskSeverity

    FDA regulatory status of manufacturing sites

    Two sites (Mandideep and Tarapur) are still awaiting FDA approval, though no pending products from these sites. — Management acknowledged

    medium

    Profitability of adjacency businesses

    Adjacency businesses (diagnostics, digital health, OTC, CDMO) are currently loss-making, impacting overall EBITDA margin. — Management acknowledged

    medium

    Competition and pricing pressure for key products

    Albuterol is facing pressure, and Tolvaptan will see competitors, potentially leading to share loss. — Management acknowledged

    medium

    Q&A highlights

    8

    “I think the MFN would definitely impact the brand side of the business much more than the generic and the focus under IRA has been on the highest value drugs. So, it is really the highest value drugs that will likely get impacted. I think that at the end of the day the value of the brand has an impact on the opportunity for generic.”

    Clarifies management's view that MFN primarily targets branded drugs, not generics, and expects litigation to challenge it.

    asked by Kunal Lakhan

    2 min read6 chapters

    Detailed Narrative

    01

    Strong FY25 Performance and Growth Drivers

    Lupin reported a stellar fiscal year 2025, achieving USD 2.7 billion in revenue and USD 625 million in EBITDA. The company saw significant growth across all key markets, with North America growing 16%, US specifically 17%, India 14%, and EMEA 22%. Gross margins improved from 64% to 69% over the last five years, reaching 69.2% in Q4 FY25, while EBITDA margins expanded from 16% to 24% over the same period, hitting 23.2% in the latest quarter.

    02

    US Business Turnaround and Complex Generics Focus

    The US business experienced a significant turnaround, growing 17% in FY25 to USD 925 million. Complex generics now account for 30% of US revenues and are projected to reach 49% in the next five years and 55% by FY30. Key product launches like Mirabegron, Tolvaptan, and Spiriva have been instrumental. The company holds the 3rd largest position in the US by prescriptions dispensed, with 4.9% market share.

    03

    India Business Expansion and Chronic Portfolio Shift

    Lupin's India business grew 14% in FY25, despite a 12% de-growth in its in-licensed portfolio due to loss of exclusivity. The focus on chronic therapy areas has increased the chronic share from sub-60% five years ago to 64% currently, with a target of 69-70% by FY30. The sales force has expanded from 5,000 to over 10,000, and the company plans to add 400-500 representatives annually, aiming for 1.2-1.3 times market growth.

    04

    Strategic Adjacencies and Future Growth Pillars

    Lupin is investing in strategic adjacencies beyond prescription medicine, including diagnostics, digital health, and OTC products. Lupin Diagnostics achieved 44% YoY revenue growth and aims to be EBITDA positive by FY27. Lupin Life (OTC) generated INR 150 crores and targets to more than double in the next 3-4 years. The company is also building a CDMO business leveraging its API capabilities, which is expected to contribute meaningfully within two years.

    05

    Capital Allocation and Financial Health

    The company has achieved a zero-debt status and reported strong free cash flow of INR 1,330 crores in FY25. ROCE has improved from 10% to 20% over the last five years, with a target to reach 27-28%. Future capital allocation will prioritize India and specialty businesses, with a potential debt-to-EBITDA ratio of around 2:1 for M&A opportunities. R&D spend, currently around 8% of sales, is expected to increase to upward of 8.5% next year, focusing on complex generics and novel products.

    06

    Regulatory and Market Landscape

    Lupin has made significant strides in compliance, with 3 out of 5 warning letter sites cleared. Two sites (Mandideep and Tarapur) are still awaiting FDA approval, but management is confident in their readiness. The company is actively engaging with the US government on bilateral trade negotiations to address tariffs and potential US manufacturing incentives. Management believes the MFN policy will primarily impact branded drugs, not generics, and expects litigation to challenge it.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.